iBio (NYSE AMERICAN:IBIO) entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial intelligence/blockchain-driven vision system for pharmaceutical manufacturing, known as TrustPoint Fabric.
Initial implementation will occur at iBio’s state-of-the-art production facility for the optimization of raw material documentation and verification activities.
Using blockchain technology, TrustPoint Fabric enables automated data generation and capture to remain immutable and fully auditable. When fully implemented, iBio aims to deliver the highest-level of compliance to the pharmaceutical industry’s standards for data integrity.
In addition, the enhanced automation capabilities are expected to lower operating costs while improving quality for clients of iBio’s biologics contract development and manufacturing services (CDMO).
“Adding this technology to our automated biologics manufacturing facility is a natural fit and may yield substantial benefits,” Robert Erwin, president of iBio, said in a statement. “The potential to reduce costs by streamlining labor intensive manual operations while improving quality is very attractive as we continue to grow our position as the leading plant-based biologics CDMO.”
Vuong Trieu, CEO of Mateon, said the platform has broad application potential across virtually all types of pharmaceutical manufacturing, including biologics, cell and gene therapy, small molecule manufacturing, bulk drug substance, fill finish, packaging and labeling.
“We envision the application of TrustPoint Fabric in iBio’s cGMP manufacturing raw material supply chain will be the first in a series of implementations, both with iBio as well as other potential EdgePoint customers,” Mr. Trieu added.
